TLIS (Talis Biomedical) Total Equity: $48.63 Mil (As of Jun. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TLIS Talis Biomedical Corp TLIS
28 GF Score
Price $2.84
View Full Analysis

What is Talis Biomedical Total Equity?

Talis Biomedical TLIS 28 Total Equity is $48.63 Mil as of Jun. 2024. GuruFocus rates TLIS with a GF Score™ of 28/100.

Talis Biomedical's total equity for the quarter that ended in Jun. 2024 was $48.63 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Talis Biomedical Total Equity Historical Data

* Premium members only.

The historical data trend for Talis Biomedical's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Talis Biomedical Total Equity Chart

Talis Biomedical Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Equity
Get a 7-Day Free Trial -21.14 -108.57 233.98 126.74 69.12

Talis Biomedical Quarterly Data
Dec18 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 96.17 81.56 69.12 56.68 48.63
TLIS
28GF Score
Talis Biomedical Corp TLIS
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Talis Biomedical Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Talis Biomedical's Total Equity for the fiscal year that ended in Dec. 2023 is calculated as

Total Equity=Total Assets(Q: Dec. 2023 )-Total Liabilities(Q: Dec. 2023 )
=94.674-25.558
=69.12

Talis Biomedical's Total Equity for the quarter that ended in Jun. 2024 is calculated as

Total Equity=Total Assets(Q: Jun. 2024 )-Total Liabilities(Q: Jun. 2024 )
=72.699-24.073
=48.63

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $48.63 Mil mean?
Talis Biomedical (TLIS) has a Total Equity of $48.63 Mil as of Jun. 2024. The total amount of equity as record on a company's balance sheet. View historical data for Talis Biomedical and its competitors.
Is Talis Biomedical's Total Equity too high?
Talis Biomedical's current Total Equity is $48.63 Mil. Overall, Talis Biomedical has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Talis Biomedical's Total Equity compare to BJDX and BBLG?
Talis Biomedical's Total Equity of $48.63 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Medical Devices & Instruments company?
A good Total Equity depends on the Medical Devices & Instruments industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Talis Biomedical and its competitors. Talis Biomedical's current Total Equity is $48.63 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Talis Biomedical stock overvalued right now?
Talis Biomedical (TLIS) has a current Total Equity of $48.63 Mil. The current Total Equity is $48.63 Mil. Talis Biomedical's overall GF Score™ is 28/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Talis Biomedical (TLIS), the current Total Equity is $48.63 Mil as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Talis Biomedical Business Description

Address 1375 West Fulton Market, Suite 700, Chicago, IL, USA, 60607
Talis Biomedical Corp is engaged in developing and commercializing products designed to enable molecular testing for infectious diseases and other conditions at the point-of-care. Its Talis One System is a molecular diagnostic platform developed to enable point-of-care testing for infectious diseases such as COVID-19.
28GF Score

Get the complete analysis for TLIS

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.84
Price